[DOI] [PubMed] [Google Scholar] [17].Nyman JS, Even JL, Jo CH, Herbert EG, Murry MR, Cockrell GE, Wahl EC, Bunn RC, Lumpkin CK, Fowlkes JL, Thrailkill KM, Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone, Bone 48 (2011) 733740, 10.1016/j.bone.2010.12.016
10.1111/j.1432-1033.1983.tb07429.x 35 FisherA
Longitudinal monitoring can identify suspicious patterns even when specific peptide tests are negative
The trial's joint chair, Professor Rury Holman of Oxford University, told delegates at the ADA that the study "provides reassurance that sitagliptin may be used safely to improve blood glucose levels in a diverse group of type 2 diabetes patients at high cardiovascular risk without impacting on rates of cardiovascular complications or heart failure." AZ added to the debate at the ADA with the presentation of data from a real-world study which found no evidence of increased risk of hospitalisation for heart failure with Onglyza compared to Januvia in patients with and without established CV disease